logo
Share SHARE
FONT-SIZE Plus   Neg

Silgan Holdings Q1 Profit Rises

Silgan Holdings Inc. (SLGN) Thursday reported an increase in profit for the first quarter, due mainly to higher revenues.

The Stamford, Connecticut-based company reported first-quarter net profit of $32.8 million or $0.47 per share, compared to $26.1 million or $0.37 per share last year.

Adjusted earnings for the quarter rose to $0.50 per share from $0.41 per share in the prior-year quarter. On average, 12 analysts polled by Thomson Reuters expected the company to earn $0.46 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter grew 9.3 percent to $768.4 million from $703.1 million in the prior-year quarter. Nine analysts had a consensus revenue estimate of $785.92 million for the quarter.

Looking ahead, the company expects second-quarter adjusted earnings of $0.55 to $0.60 per share. Analysts currently expect the company to earn $0.57 per share for the quarter.

The company confirmed its full-year 2012 earnings guidance in the range of $2.80 to $2.90 per share. Analysts currently expect earnings of $2.88 per share for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Foodservice distributor Sysco Corp. (SYY) reported a third-quarter profit that grew 22.7 percent from last year, while quarterly sales increased 2.2 percent. Both earnings per share and revenue for the quarter beat analysts' expectations. Halliburton Co. (HAL) and Baker Hughes Inc. (BHI) announced Sunday that they terminated the merger agreement they entered into in November 2014, effective April 30, 2016. In connection with the termination of the merger agreement, Halliburton will pay Baker Hughes the termination fee of $3.5 billion... The bench to bedside journey of drugs is fraught with challenges. It is estimated that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and out of those 5, only 1 may pass through all the regulatory hurdles needed to reach pharmacy shelves.
comments powered by Disqus
Follow RTT